Published in JAMA on January 11, 2006
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ (2013) 5.08
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation (2017) 2.76
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J (2011) 2.29
Survival in patients with poorly compressible leg arteries. J Am Coll Cardiol (2012) 2.25
Effect of proton-pump inhibitors on the risk of lower gastrointestinal bleeding associated with NSAIDs, aspirin, clopidogrel, and warfarin. J Gastroenterol (2015) 2.03
A prevalence of cardiometabolic risk factors among a rural Yoruba south-western Nigerian population: a population-based survey. Cardiovasc J Afr (2010) 1.86
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J (2009) 1.84
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension (2009) 1.81
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J (2010) 1.74
Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol (2013) 1.68
The Enhancing Secondary Prevention in Coronary Artery Disease trial. CMAJ (2009) 1.57
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J (2014) 1.55
The impact of cardiovascular risk-factor profiles on blood pressure control rates in adults from Canada and the United States. Can J Cardiol (2013) 1.50
Influence of Obesity and Metabolic Disease on Carotid Atherosclerosis in Patients with Coronary Artery Disease (CordioPrev Study). PLoS One (2016) 1.38
Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation (2011) 1.27
Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ Cardiovasc Genet (2011) 1.26
The impact of prevention on reducing the burden of cardiovascular disease. Diabetes Care (2008) 1.25
Factors associated with treatment compliance in hypertension in southwest Nigeria. J Health Popul Nutr (2011) 1.13
Awareness, treatment, and control of vascular risk factors among stroke survivors. J Stroke Cerebrovasc Dis (2010) 1.12
The evolving epidemiology of acute coronary syndromes. Nat Rev Cardiol (2010) 1.09
Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart (2007) 1.05
Case management for blood pressure and lipid level control after minor stroke: PREVENTION randomized controlled trial. CMAJ (2014) 1.03
Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. Eur Heart J (2008) 1.02
Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Mayo Clin Proc (2011) 1.00
Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). BMC Public Health (2010) 0.99
Missed opportunities for the secondary prevention of cardiovascular disease in Canada. Can J Cardiol (2007) 0.99
Age and Gender Disparities in Evidence-based Treatment for Coronary Artery Disease in the Community: A Cross-sectional Study. Indian J Community Med (2011) 0.97
Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. BMC Public Health (2011) 0.96
Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. Clin Res Cardiol (2009) 0.94
Current utility of the ankle-brachial index (ABI) in general practice: implications for its use in cardiovascular disease screening. BMC Fam Pract (2014) 0.94
Clustering of Major Cardiovascular Risk Factors and the Association with Unhealthy Lifestyles in the Chinese Adult Population. PLoS One (2013) 0.93
Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. Vasc Health Risk Manag (2006) 0.93
Cardiac evaluation of liver transplant candidates. World J Gastroenterol (2008) 0.93
High prevalence of peripheral arterial disease in Korean patients with coronary or cerebrovascular disease. J Korean Med Sci (2012) 0.91
Peripheral artery disease assessed by ankle-brachial index in patients with established cardiovascular disease or at least one risk factor for atherothrombosis--CAREFUL study: a national, multi-center, cross-sectional observational study. BMC Cardiovasc Disord (2011) 0.90
Ankle-Brachial Index determination and peripheral arterial disease diagnosis by an oscillometric blood pressure device in primary care: validation and diagnostic accuracy study. BMJ Open (2012) 0.90
How do family physicians communicate about cardiovascular risk? Frequencies and determinants of different communication formats. BMC Fam Pract (2011) 0.89
Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol (2010) 0.89
N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure. Eur J Epidemiol (2009) 0.89
Prevalence of asymptomatic critical carotid artery stenosis in Korean patients with chronic atherosclerotic lower extremity ischemia: is a screening carotid duplex ultrasonography worthwhile? J Korean Med Sci (2010) 0.88
Barriers to cardiovascular risk prevention and management in Germany--an analysis of the EURIKA study. Vasc Health Risk Manag (2012) 0.88
Increased arachidonic acid-induced thromboxane generation impairs skeletal muscle arteriolar dilation with genetic dyslipidemia. Microcirculation (2008) 0.87
Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients. Diabetes Care (2008) 0.87
Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients--a longitudinal observational study. Cardiovasc Diabetol (2009) 0.87
The LOX-1 Scavenger Receptor and Its Implications in the Treatment of Vascular Disease. Cardiol Res Pract (2012) 0.87
Criticial limb ischemia: epidemiology. Methodist Debakey Cardiovasc J (2013) 0.87
Optimal management of infrainguinal arterial occlusive disease. Vasc Health Risk Manag (2014) 0.86
Secondary prevention after minor stroke and TIA - usual care and development of a support program. PLoS One (2012) 0.86
Comprehensive cardiovascular risk management--what does it mean in practice? Vasc Health Risk Manag (2007) 0.86
Prognostic value of cardiovascular disease status: the Leiden 85-plus study. Age (Dordr) (2012) 0.86
Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment. BMJ Open (2016) 0.85
The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. PPAR Res (2008) 0.85
Systemic risk score evaluation in ischemic stroke patients (SCALA): a prospective cross sectional study in 85 German stroke units. J Neurol (2007) 0.85
Cardiovascular risk in survivors of stroke. Am J Prev Med (2007) 0.84
Current strategies for ischemic stroke prevention: role of multimodal combination therapies. J Neurol (2007) 0.84
Relevance of stroke subtype in vascular risk prediction. Neurology (2013) 0.84
Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm. Heart Vessels (2013) 0.84
Impaired Aβ clearance: a potential link between atherosclerosis and Alzheimer's disease. Front Aging Neurosci (2015) 0.84
A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240]. Implement Sci (2006) 0.83
Peripheral artery disease: potential role of ACE-inhibitor therapy. Vasc Health Risk Manag (2008) 0.83
Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets (2009) 0.83
Expression of the leptin receptor in different types of vascular lesions. Histochem Cell Biol (2007) 0.83
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. Vasc Health Risk Manag (2007) 0.83
Relationship between sleep duration and clustering of metabolic syndrome diagnostic components. Diabetes Metab Syndr Obes (2011) 0.83
Trimethylamine N-Oxide and Mortality Risk in Patients With Peripheral Artery Disease. J Am Heart Assoc (2016) 0.82
NT-proBNP best predictor of cardiovascular events and cardiovascular mortality in secondary prevention in very old age: the Leiden 85-plus Study. PLoS One (2013) 0.82
Catheter Ablation of Ventricular Arrhythmias via the Radial Artery in a Patient With Prior Myocardial Infarction and Peripheral Vascular Disease. Korean Circ J (2012) 0.82
Management of atherothrombotic risk factors in high-risk Canadian outpatients. Can J Cardiol (2009) 0.82
Presence of peripheral arterial disease predicts loss of residual renal function in incident CAPD patients. Perit Dial Int (2011) 0.82
Both vascular endothelial growth factor and soluble Flt-1 are increased in type 2 diabetes but not in impaired fasting glucose. J Investig Med (2010) 0.82
Spectral CT of carotid atherosclerotic plaque: comparison with histology. Eur Radiol (2012) 0.81
Methods of symptom evaluation and their impact on peripheral artery disease (PAD) symptom prevalence: a review. Vasc Med (2013) 0.81
Asymptomatic coronary heart disease in patients with type 2 diabetes with vascular complications: a cross-sectional study. BMJ Open (2011) 0.81
Risk Factors of Coronary Artery Disease in Secondary Prevention--Results from the AtheroGene--Study. PLoS One (2015) 0.81
Genome-Wide Association Study of Peripheral Arterial Disease in a Japanese Population. PLoS One (2015) 0.80
Cardiovascular events in patients with atherothrombotic disease: a population-based longitudinal study in Taiwan. PLoS One (2014) 0.80
The role of trefoil factor family in apparently healthy subjects administrated gastroprotective agents for the primary prevention of gastrointestinal injuries from low-dose acetylsalicylic acid: a preliminary study. J Clin Biochem Nutr (2011) 0.80
Atherosclerotic disease and risk factor modification in Saudi Arabia: a call to action. Vasc Health Risk Manag (2012) 0.80
Dual pH- and temperature-responsive microparticles for protein delivery to ischemic tissues. Acta Biomater (2013) 0.80
Association of short sleep duration with impaired glucose tolerance or diabetes mellitus. J Diabetes Investig (2011) 0.80
Imaging coronary and extracoronary atherosclerosis: feasibility and impact of whole-body computed tomography angiography. Eur Radiol (2009) 0.80
Laparoscopic and robot-assisted laparoscopic digestive surgery: Present and future directions. World J Gastroenterol (2016) 0.80
Clinical characteristics of silent myocardial ischemia diagnosed with adenosine stress 99mTc-tetrofosmin myocardial scintigraphy in Japanese patients with acute cerebral infarction. Heart Vessels (2011) 0.80
Clinical presentation and short-term outcome of acute coronary syndrome in native young Saudi population. J Saudi Heart Assoc (2012) 0.79
Genetic determinants of the ankle-brachial index: a meta-analysis of a cardiovascular candidate gene 50K SNP panel in the candidate gene association resource (CARe) consortium. Atherosclerosis (2012) 0.79
One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry. Can J Cardiol (2010) 0.79
Metabolic abnormalities linked to an increased cardiovascular risk are associated with high-grade prostate cancer: a single biopsy cohort analysis. Prostate Cancer Prostatic Dis (2015) 0.79
"Addressing the impact of stroke risk factors in a case control study in tertiary care hospitals": a case control study in Tertiary Care Hospitals of Peshawar, Khyber Phukhtoonkhwa (KPK) Pakistan. BMC Res Notes (2013) 0.79
Physician perception of blood pressure control and treatment behavior in high-risk hypertensive patients: a cross-sectional study. PLoS One (2011) 0.79
Aspirin use and knowledge in the community: a population- and health facility based survey for measuring local health system performance. BMC Cardiovasc Disord (2014) 0.79
Risk Factors and Event Rates in Patients With Atherothrombotic Disease in Germany: Results of the REACH Registry. Dtsch Arztebl Int (2008) 0.79
Low awareness of stroke guidelines and preference for Chinese herbs in community physicians: a national survey in China. Ann Transl Med (2014) 0.78
Cardiovascular secondary prevention in high-risk patients: a randomized controlled trial sub-study. BMC Cardiovasc Disord (2015) 0.78
Intensified secondary prevention intending a reduction of recurrent events in TIA and minor stroke patients (INSPiRE-TMS): a protocol for a randomised controlled trial. BMC Neurol (2013) 0.78
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
Obesity and the risk of heart failure. N Engl J Med (2002) 12.58
Universal definition of myocardial infarction. Circulation (2007) 11.69
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med (2006) 7.62
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol (2003) 7.47
Predictors of new-onset kidney disease in a community-based population. JAMA (2004) 7.45
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature (2004) 7.21
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation (2006) 5.97
Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA (2006) 5.78
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA (2004) 5.34
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med (2004) 4.92
Trends in cardiovascular complications of diabetes. JAMA (2004) 4.74
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA (2004) 4.63
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Impact of obesity on plasma natriuretic peptide levels. Circulation (2004) 4.46
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 4.24
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation (2003) 4.09
Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet (2010) 4.07
Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study. Am J Hum Genet (2002) 4.07
Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care (2002) 3.96
Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation (2010) 3.95
Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA (2007) 3.79
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA (2005) 3.72
Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circ J (2012) 3.70
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2014) 3.59
Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med (2003) 3.54
Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care (2004) 3.37
C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation (2004) 3.25
Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation (2006) 3.15
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07
Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke (2004) 3.07
Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation (2004) 3.02
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01
Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol (2006) 2.98
Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation (2004) 2.90